top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Feb 9, 2021
Demystifying INMETRO and ANATEL certification for health products
Feb 9, 2021
API: Why control it?
Feb 9, 2021
CTD - Why?
Feb 9, 2021
Which points generate the most rejections and demands in innovative drug processes?
Feb 9, 2021
DDCM: what are the points that generate the most demands at ANVISA (Part 2)?
Feb 9, 2021
DDCM- What are the most demanding requirements by ANVISA?
Feb 9, 2021
Biosimilars - An investment with excellent long-term prospects
Feb 9, 2021
Biosimilars - Can Marketing activities make a Difference? 6 reflections on the theme
Feb 9, 2021
Practical aspects of biosimilar registration
Feb 9, 2021
Comparability of biosimilars: unraveling this enigma
Feb 9, 2021
The biotechnological challenge of the national pharmaceutical industry has already begun
Feb 9, 2021
ANVISA’S new era: is the regulatory sector prepared for this?
Feb 9, 2021
New Efficacy and Safety Analysis Roadmap for Synthetic Drug Registration
Feb 9, 2021
Clinical Research in Brazil: there is still a lot of room to grow
Feb 9, 2021
5 tips on how to maximize your product results from the early stages of development
Feb 9, 2021
Clinical studies: 7 tips to maximize your resources and enable more efficient projects
Feb 9, 2021
New regulatory framework for food supplements
Feb 9, 2021
New rules for outsourcing in the pharmaceutical industry: many possibilities!
Feb 9, 2021
What's new in the Good Clinical Practices E6 Guide published by ICH
1
2
3
4
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
